Table 1.
Total Sample (N=302) | ADHD Group (n=162) | Comparison Group (n=140) | Group Differences | |
---|---|---|---|---|
M±SD | M±SD | M±SD | ||
Age | 13.17±0.40 | 13.17±0.41 | 13.18±0.40 | t=0.26, p=.80 |
Primary Household Income ($USD) | 93,073±34,856 | 84,875±35,864 | 102,500±31,213 | t=4.56, p<.001 |
N (%) | N (%) | N (%) | ||
Female | 135 (44.7) | 57 (35.2) | 78 (55.7) | X2=12.80, p<.001 |
Race | X2=9.17, p=.06 | |||
White | 247 (81.8) | 129 (79.6) | 118 (84.3) | |
Black | 16 (5.3) | 12 (7.4) | 4 (2.9) | |
Asian | 14 (4.6) | 4 (2.5) | 10 (7.1) | |
American Indian/Alaskan | 1 (0.3) | 1 (0.6) | 0 (0) | |
Bi/Multiracial | 24 (7.9) | 16 (9.9) | 8 (5.7) | |
Hispanic/Latinx | 14 (4.6) | 7 (4.3) | 7 (5.0) | X2=0.08, p=.78 |
Highest Maternal Education | ||||
HS degree or less | 14 (4.3) | 10 (6.2) | 4 (2.9) | X2=7.82, p=.05 |
Partial college/vocational | 56 (18.5) | 33 (20.4) | 23 (16.4) | |
College graduate | 126 (41.7) | 73 (45.1) | 53 (37.9) | |
Graduate/professional degree | 106 (35.1) | 46 (28.4) | 60 (42.9) | |
Medication Use | ||||
ADHD (any) | 96 (31.8) | 96 (59.3) | 0 (0) | X2=121.63, p<.001 |
Methylphenidate | 48 (15.9) | 48 (29.6) | 0 (0) | X2=49.32, p<.001 |
Amphetaminea | 47 (15.6) | 47 (29.0) | 0 (0) | X2=48.10, p<.001 |
Non-stimulantb | 20 (6.6) | 20 (12.3) | 0 (0) | X2=18.51, p<.001 |
Other Psychiatric (any) | 29 (9.6) | 22 (13.6) | 7 (5) | X2=6.37, p=.01 |
Antidepressant | 24 (7.9) | 18 (11.1) | 6 (4.3) | X2=4.78, p=.03 |
Antianxiety | 2 (0.7) | 1 (0.6) | 1 (0.7) | X2=0.01, p=1.00e |
Antipsychotic | 3 (1.0) | 3 (1.9) | 0 (0) | X2=2.62, p=.25b |
Other psychiatric diagnosesc | 107 (35.4) | 74 (45.7) | 33 (23.6) | X2=16.04, p<.001 |
Any externalizing (ODD/CD) | 41 (13.6) | 35 (21.6) | 6 (4.3) | X2=19.20, p<.001 |
Any anxiety | 73 (24.2) | 46 (28.4) | 27 (19.3) | X2=3.40, p=.07 |
Any depression | 24 (7.9) | 16 (9.9) | 8 (5.7) | X2=1.78, p=.18 |
Note. ADHD=attention-deficit/hyperactivity disorder. ODD/CD=oppositional defiant disorder/conduct disorder. Any anxiety=presence of generalized anxiety disorder, social phobia, obsessive-compulsive disorder, and/or posttraumatic stress disorder (PTSD). Any depression=presence of major depression or dysthymia.
Includes amphetamine and mixed amphetamine salts.
Includes guanfacine, atomoxetine, and clonidine.
Presence of comorbid mental health diagnosis based on parent or adolescent report (only parents were administered ODD and PTSD modules) during the diagnostic interview.